Bone drug switch: can new meds prevent fracture risk after stopping denosumab?
NCT ID NCT05091099
First seen Nov 19, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study looked at 44 postmenopausal women and men over 50 who had taken Denosumab for at least three years to treat osteoporosis. Researchers tested whether switching to Alendronate or Zoledronate could prevent bone density loss after stopping Denosumab. The goal was to find the best way to keep bones strong and reduce fracture risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital, Yunlin branch
Douliu, Yunlin County, 640, Taiwan
Conditions
Explore the condition pages connected to this study.